disease was defined as any clinical history of myocardial infarction, percutaneous coronary intervention, coronary artery bypass surgery, or angiographic evidence of coronary artery disease (!50% stenosis) in !1 major coronary artery. Glycemic status and clinical definition of diabetes mellitus, "prediabetes," and nondiabetes were defined by the latest practice guidelines on the basis of fasting glucose and glycosylated hemoglobin (HbA 1c ) levels (fasting glucose <100 mg/dl and HbA 1c <5.7% for normal subjects; fasting glucose !126 mg/dl or HbA 1c !6.5% or currently taking glucose-lowering medications for diabetes mellitus; neither normal nor diabetes mellitus for prediabetes). 7 Adjudicated outcomes were ascertained over the ensuing 3 years for all subjects after enrollment. The prospective determination of clinical outcomes was made by the research personnel contacting participants independent of study investigators, with prespecified criteria and confirmation by review of documentation independent of the investigators. Major adverse cardiovascular events (MACEs) were defined as death, nonfatal myocardial infarction, or nonfatal cerebrovascular accident after enrollment. Blood samples were collected before the administration of heparin, placed on ice, aliquoted, and frozen at À80
F within 2 hours of collection.
All laboratory assays, including hsCRP, BNP, MPO, apolipoprotein A1, apolipoprotein B100, and creatinine, were performed using the Abbott ARCHITECT ci8200 platform (Abbott Diagnostics Inc., Abbott Park, Illinois). The intra-and interassay coefficients were 4% and 2.4% for hsCRP, 2.6% and 3.5% for BNP, and 6.2% and 4.1% for MPO, respectively. Student's t tests or Wilcoxon's rank-sum tests for continuous variables and chi-square tests for categorical variables were used to examine the differences between the groups. A cardiac biomarker score (CBS) was given to each group on the basis of whether it had a positive value for each respective biomarker. We used cutoffs for each of the 3 biomarkers (BNP >100 pg/ml, hsCRP >2.0 ng/L, and MPO >322 pmol/L) on the basis of previous cutoffs used for the respective markers, as reported in previous studies. 2, 4, 8 Each of the groups was categorized as 0, 1, 2, or 3 as a measure of how many biomarkers were deemed positive, which was defined as the CBS. Kaplan-Meier analysis with Cox proportional-hazards regression was used for time-to-event analysis to determine hazard ratios (HRs) and 95% confidence intervals (95% CIs) for MACEs. Unadjusted trends for all-cause mortality rates as well as rates of nonfatal myocardial infarction or stroke with increasing quartiles of MPO, hsCRP, and BNP were evaluated using the Cochran-Armitage test using a time-to-event approach. Adjustments were made for individual traditional cardiac risk factors (including age, gender, low-density and high-density lipoprotein cholesterol, systolic blood pressure, former or current cigarette smoking, diabetes mellitus, apolipoprotein B100/apolipoprotein A1 ratio, history of myocardial infarction, and creatinine clearance) to predict incident 3-year risk for MACEs. Net reclassification analysis was performed with the 2 Cox models adjusted for traditional risk factors. Cutoff values for net reclassification index estimation used a ratio of 6:3:1 for low-, medium-, and high-risk categories. All analyses were performed using R version 8.02 (R Foundation for Statistical Computing, Vienna, Austria), and p values <0.05 were considered statistically significant. Table 1 describes the baseline characteristics of our study population and is stratified according to glycemic status. The median levels of hsCRP, BNP, and MPO were 2.00 pg/ml (interquartile range 0.91 to 4.47), 83 pg/ml (interquartile range 34 to 200), and 103 pmol/L (interquartile range 70 to 195), respectively. All 3 biomarkers were notably elevated in patients with diabetes compared to those with prediabetes or nondiabetes. Table 2 represents the prognostic value of individual cardiac biomarkers in our study cohort. All 3 cardiac biomarkers provided incremental risk prediction in our study cohort. After adjusting for traditional risk factors, including Framingham risk factors, log-transformed BNP, hsCRP, and MPO each remained independent predictors of incident MACEs at 3-year follow-up.
Results
By summing the number of positive cardiac biomarkers, we developed a CBS that integrated the risk profile of our study cohort. As illustrated in Figure 1 , the CBS provided incremental prognostic value, as displayed by Kaplan-Meier analysis. As listed in Table 3 , the CBS, based on the sum total of positive biomarkers, provided independent prediction of future risk for incident MACEs at 3 years (HR 7.61, 95% CI 4.98 to 11.65, p <0.001), even after adjustment for traditional risk factors (HR 6.11, 95% CI 3.98 to 9.38, p <0.001), in addition to apolipoprotein B100/apolipoprotein A1 ratio (HR 6.11, 95% CI 3.98 to 9.38, p <0.001) ( Table 3 ). The ability of the CBS to provide incremental risk stratification can be seen in subgroups of patients with primary and secondary prevention, as well as those with maximal coronary artery stenoses <50% and !50% (Figure 2) . A higher CBS predicted future risk for MACEs at 3 years regardless of age, gender, body mass index, diabetes mellitus, hypertension, renal insufficiency, or previous myocardial infarction (p <0.01 for all). Use of the CBS on top of traditional risk factors was also shown to reclassify subjects (net reclassification index 12.86%, p <0.001; integrated discrimination improvement 12.0%, p <0.001; C-statistic 66.9% vs 71.1%, p <0.001).
We further analyzed our study cohort according to glycemic status and different subgroups. The capability of the CBS to stratify patients' risk profiles within subjects with diabetes mellitus, prediabetes, or normal glycemic status (neither prediabetes nor diabetes) on the basis of practice Figure 3 ). In a similar manner, after adjustment for HbA 1c , the prognostic value of the CBS was preserved. Furthermore, the prognostic value of the CBS was similar regardless of age, gender, body mass index, diabetes mellitus, hypertension, renal insufficiency, or previous myocardial infarction (p <0.01 for all).
Discussion
Although previous studies have examined similar multimarker strategies for risk prediction, many of them used biomarkers that are not commonly used or available in the clinical practice settings. The key finding in this study is the incremental prognostic value of all 3 clinically available plasma cardiac biomarkers beyond standard evaluation of classic Framingham risk factors, renal function, and apolipoprotein B100/apolipoprotein A1 ratio in troponin-negative, stable cardiac patients who undergo coronary angiography. We further identified comparable prognostic value within subsets of patients with prediabetes or nondiabetes or those with no significantly obstructive coronary artery disease, further underscoring the potential for a multimarker approach in identifying vulnerable patients within cohorts that may allow targeted risk factor modifications and more aggressive preventive interventions.
HsCRP is the most common systemic inflammatory biomarker used in clinical practice, particularly in patients with diabetes mellitus and potential response to statin therapy. 4,9 11 Elevated levels have also been associated with altered cardiac structure and function, as well as adverse long-term consequences. 12 In addition, hsCRP has been suggested to play a role in atherosclerosis and its complications, although genetic studies suggest that the association with adverse outcomes may not be causal. 13, 14 In contrast, MPO has been shown to directly promote the catalytic consumption of nitric oxide, leading to the development of endothelial dysfunction. 15 17 MPO is a leukocyte-derived hemoprotein that has been linked in the development and subsequent instability of atherosclerotic plaques. 18, 19 Previous studies have shown MPO to have prognostic significance in subjects with unstable angina, as well as after acute myocardial infarction, acute heart failure, and chronic stable heart failure, as well as healthy middleaged and elderly subjects. 3,18,20 23 Recently, it was also found that MPO remained a statistically significant prognostic indicator of cardiovascular risk in a large stable CAD population. 8 In contrast, the natriuretic peptide family is a group of endogenous peptides primarily produced in the heart that provide counter-regulatory effects on a wide range of organs to maintain perfusion and reduce overloading status of the vasculature. 24 BNP has recently been shown to be elevated in acute coronary syndromes without necessarily having myocardial infarction, and it may reflect not only the underlying impairment of left ventricular function but also the severity of the ischemic episode. 25 Altogether, this combination of biomarkers offers complementary mechanistic insights during cardiac evaluation in stable patients, although only a small subset of patients demonstrated positive results for all 3 biomarkers in our relatively stable patient cohort.
Our study further explored the impact of glycemic control on the prognostic value of cardiac biomarkers, particularly as the latest guidelines have highlighted a subset of "at-risk" patients that is thought to have heightened risk for developing diabetes mellitus and future cardiovascular risk. 7, 26 We observed a graded increase in the levels of each of our corresponding biomarkers as patients were determined to have nondiabetes, prediabetes, and diabetes. The overall trend toward increased risk for MACEs was similar among all groups on the basis of their CBS. Similarly, the CBS provided significant prognostic value among subjects for whom no significant angiographic evidence of stenosis was discovered, who are most often considered to have lower risk.
The strength of this study is the considerable size of the patient population. This contemporary cohort of stable cardiac patients is representative of current clinical practice. The focus on the homogenous elective coronary angiography population and the availability and inclusion of only biomarkers cleared by the United States Food and Drug Administration for the analyses strengthen the study, as the present biomarkers, although clinically available for use, are not routinely measured. Including them in the analysis provides insight into a nonacute, troponin-negative population, which has yet to be thoroughly investigated. Incremental contributions of these cardiac biomarkers toward risk stratification above and beyond standard clinical and biochemical characteristics in this population have also not been thoroughly tested, particularly with rigorous statistical evaluation or covariate adjustments. Potential weaknesses of the study population arise because a clinical trial cohort of patients who underwent coronary angiography was used, and thus resulting in, particularly because they were already undergoing cardiac evaluation. Moreover, our data relate to prognostic rather than diagnostic applications of these biomarkers. We also did not have high-sensitivity troponin assays in this cohort, which was deemed troponin negative by currently approved troponin assays. Last, although our results were based on previously used cut points, they may overestimate the strengths of the risk relations. With different studies using different cutoff values for different populations, there is a need to identify clinically useful cut points on the basis of consensus of results.
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